Physician profile
Jochen H Lorch
NPI 1518913094
$26,160.43
in general payments reported to CMS, 2019-2025
18 companies · $3,900 in 2025
The $3,900 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,341 · 2020: $1,000 · 2022: $2,854 · 2023: $1,627 · 2024: $11K · 2025: $3,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Honoraria: $2,025 · Travel and Lodging: $1,647 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,320 · Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,258.75 |
| Honoraria | $2,025.00 |
| Travel and Lodging | $1,647.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,320.00 |
| Food and Beverage | $713.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,102.12 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $6,341.17 | 2019-2020 | |
| Exelixis INC. | $4,297.17 | 2022-2025 | Cabometyx |
| Eisai INC. | $4,121.25 | 2024-2025 | |
| Coherus Oncology, INC. | $2,298.46 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $1,762.50 | 2025 | |
| Sk Life Science, INC. | $104.93 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $50.42 | 2022-2023 | Libtayo |
| Seagen INC. | $25.36 | 2022 | |
| Morphosys, US INC. | $22.72 | 2022 | |
| Merck Sharp & Dohme LLC | $19.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.53 | 2023 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jochen Lorch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.